### **Accepted Manuscript**

Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis

Ioanna Ninou, Eleanna Kaffe, Stefan Müller, David C. Budd, Christopher S. Stevenson, Christoph Ullmer, Vassilis Aidinis

PII: \$1094-5539(18)30181-0

DOI: 10.1016/j.pupt.2018.08.003

Reference: YPUPT 1741

To appear in: Pulmonary Pharmacology & Therapeutics

Received Date: 18 July 2018

Accepted Date: 16 August 2018

Please cite this article as: Ninou I, Kaffe E, Müller S, Budd DC, Stevenson CS, Ullmer C, Aidinis V, Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis, *Pulmonary Pharmacology & Therapeutics* (2018), doi: 10.1016/j.pupt.2018.08.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



#### ACCEPTED MANUSCRIPT

# Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis

Ioanna Ninou<sup>a</sup>, Eleanna Kaffe<sup>a</sup>, Stefan Müller<sup>b</sup>, David C. Budd<sup>c,d</sup>, Christopher S. Stevenson<sup>c,e</sup>, Christoph Ullmer<sup>b</sup>, and Vassilis Aidinis<sup>a,\*</sup>

\*Correspondence: Vassilis Aidinis <u>V.Aidinis@Fleming.gr</u>

Keywords: Autotaxin (ATX), lysophospholipase D, lysophosphatidic acid (LPA), lysophosphatidic acid receptor 1 (LPAR1), pulmonary fibrosis

<sup>&</sup>lt;sup>a</sup> Division of Immunology, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece

<sup>&</sup>lt;sup>b</sup>Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland

<sup>&</sup>lt;sup>c</sup>Pharma Research and Early Development, F. Hoffmann-La Roche Inc., Nutley, NJ, USA

<sup>&</sup>lt;sup>d</sup>Current address: Pulmonary Vascular Injury Discovery Performance Unit, GlaxoSmithKline Medicines Research Centre, Stevenage, UK

<sup>&</sup>lt;sup>e</sup>Current address: Janssen Research & Development, Johnson and Johnson Innovation Centre, London, UK

### Download English Version:

## https://daneshyari.com/en/article/9954967

Download Persian Version:

https://daneshyari.com/article/9954967

<u>Daneshyari.com</u>